[3H]pirenzepine and (-)-[3H]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. I. Characterization and regulation of agonist binding to putative muscarinic subtypes.
The binding and regulation of selected muscarinic agonists to putative subtypes in rat cerebral cortex and heart were studied. Parallel inhibition studies of [3H]pirenzepine ([3H]PZ) and (-)-[3H]quinuclidinylbenzilate [(-)-[3H]QNB]-labeled membranes were done with and without 30 microM guanyl-5'-yl imidodiphosphate [Gpp(NH)p] at 25 degrees C in 10 mM Na-K-phosphate buffer which enhances PZ binding affinity and in modified Krebs-phosphate buffer, which mimics physiological conditions. Classical agonists such as carbachol, oxotremorine and acetylcholine inhibited (-)-[3H]QNB binding to membranes with shallow Hill values (nH less than 1), were better fit to a 2-state model, were Gpp(NH)p-regulated and showed lower affinity in modified Krebs-phosphate buffer than in 10 mM Na-K-phosphate buffer. Some agonists were not significantly better fit to a 2-state model in [3H]PZ-labeled cortical membranes, especially in 10 mM Na-K-phosphate buffer. Whereas putative M1 and M2 binding sites distinguished by PZ possessed multiple agonist affinity states, as judged by carbachol, and agonist binding to [3H]PZ-labeled sites were Gpp(NH)p modulated, the partial agonist pilocarpine and nonclassical agonist McN-A-343 [3-(m-chlorophenylcarbamoyloxy)-2-butynyl trimethylammonium chloride] showed little Gpp(NH)p-induced shift in [3H]PZ-labeled cortical membranes in physiological conditions. Agonist binding to (-)-[3H]QNB-labeled putative M2 cardiac sites was more sensitive to Gpp(NH)p than (-)-[3H]QNB-labeled cortical sites. Carbachol and acetylcholine showed significant selectivity for putative M2 sites.(ABSTRACT TRUNCATED AT 250 WORDS)
D000109:Acetylcholine / Q000378:metabolism; D000818:Animals; D001570:Benzodiazepinones / Q000378:metabolism*; D002021:Buffers; D002217:Carbachol / Q000378:metabolism; D002540:Cerebral Cortex / Q000378:metabolism*; D006165:Guanylyl Imidodiphosphate / Q000494:pharmacology; D066298:In Vitro Techniques; D008297:Male; D009206:Myocardium / Q000378:metabolism*; D010277:Parasympathomimetics / Q000378:metabolism*; D010890:Pirenzepine; D011812:Quinuclidines / Q000378:metabolism*; D011813:Quinuclidinyl Benzilate / Q000378:metabolism*; D051381:Rats; D011919:Rats, Inbred Strains; D011976:Receptors, Muscarinic / Q000032:analysis / Q000378:metabolism*; D014316:Tritium
D001570:Benzodiazepinones; D002021:Buffers; D010277:Parasympathomimetics; D011812:Quinuclidines; D011976:Receptors, Muscarinic; D014316:Tritium; D006165:Guanylyl Imidodiphosphate; D010890:Pirenzepine; D011813:Quinuclidinyl Benzilate; D002217:Carbachol; D000109:Acetylcholine